Pregnancy-associated or Puerperium-associated Acute Stroke
Conditions
Keywords
Acute stroke, Pregnancy, Puerperium, Clinical characteristics, Prognosis
Brief summary
The objectives of this study are: (1) to describe the detailed clinical characteristics and prognosis of ASPP patients in order to explore the risk factors of ASPP, and to compare the short-term and long-term functional recovery outcomes between them and their controls; (2) to evaluate the risk of recurrent stroke, particularly during subsequent pregnancies, in ASPP patients; (3) to assess the short-term and long-term outcomes of their offsprings and their future development status. This study is divided into three parts. The first part is a case-control study to explore the risk factors of ASPP and the predictors of the prognosis of ASPP patients. The second part is a cohort study to evaluate the impact of ASPP on the risk of recurrent stroke. The third part is a cohort study to assess the impact of ASPP on the short-term and long-term outcomes of their offsprings by comparing the offsprings of ASPP patients with the offsprings of non-ASPP participants.
Interventions
None listed
Sponsors
Study design
Eligibility
Inclusion criteria
1\. Case-control Study and Cohort Study on Recurrent Stroke Risk: Inclusion Criteria: 1. Female patients ≥18 years of age; 2. Patients or their legally acceptable representatives or relatives agree to collect personal information for this study and sign an oral or online written informed consent.
Exclusion criteria
1. Patients or their legally acceptable representatives or relatives refuse follow-up; 2. Patients missing critical baseline demographic, clinical or neuroimaging data. 2\. Cohort Study on Offspring Outcomes: Inclusion Criteria: 1. Female patients ≥18 years of age; 2. Patients in pregnancy or within 6 weeks postpartum; 3. Patients or their legally acceptable representatives or relatives agree to collect personal information for this study and sign an oral or online written informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Age & Stages Questionnaires scores | At follow-up (assessed between July 2024 to October 2024) | Age & Stages Questionnaires, Third Edition (ASQ-3) scores of offsprings via online self-evaluation. ASQ-3 is divided into 5 subdomains. Scores of each subdomain range from 0 to 60, with higher scores indicating better outcomes. |
| Long-term modified Ranking Scale scores | At follow-up (assessed between July 2024 to October 2024) | The modified Ranking Scale (mRS) scores of ASPP and other comparison participants evaluated by specialists. The mRS scores range from 0 to 6, with higher scores indicating worse outcomes. |
| Recurrent strokes | At follow-up (assessed between July 2024 to October 2024) | Participants who suffer from recurrent stroke events confirmed by neuroimaging |
| Apgar scores | At 1 minutes, 5 minutes and 10 minutes after delivery | Apgar scores of newborns evaluated by specialists. Apgar scores range from 0 to 10, with higher scores indicating better outcomes. Apgar score 8-10 is considered as no asphyxia, 4-7 is considered as mild asphyxia, 0-3 is considered as severe asphyxia. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Intrauterine death or stillbirth | Before or at delivery | Dead fetus in the uterus at any trimester of pregnancy, or birth of a dead infant after 28+1 gestational weeks |
| Critical illness of offsprings | At follow-up (assessed between July 2024 to October 2024) | Offsprings requiring hospitalization due to diagnosed diseases within 15 years after birth, including neurological diseases (e.g. epilepsy, cerebral palsy), cardiovascular diseases (e.g. congenital heart disease), gastrointestinal diseases (e.g. necrotizing enterocolitis), respiratory diseases (e.g. allergic asthma), urological diseases (e.g. hypospadias), hematological and immunological diseases and other major diseases |
| Short-term modified Ranking Scale scores | At discharge (assessed up to 5 days) | The modified Ranking Scale (mRS) scores of ASPP and other comparison participants evaluated by specialists. The mRS scores range from 0 to 6, with higher scores indicating worse outcomes. |
| Strokes during subsequent pregnancies | During subsequent pregnancies (assessed up to 5 days after the 6-week postpartum period of subsequent pregnancies) | Participants who suffer from stroke events during any subsequent pregnancy |
Other
| Measure | Time frame | Description |
|---|---|---|
| Length of hospitalization | Between admission and discharge (assessed up to 5 days) | Time span of hospitalization as a resulting from stroke treatment |
Countries
China